REG - Poolbeg Pharma PLC - POLB 001 European Patent granted

Poolbeg PharmaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251120:nRST2434Ia&default-theme=true

RNS Number : 2434I  Poolbeg Pharma PLC  20 November 2025

 

Poolbeg Pharma plc

 

POLB 001 European Patent granted

 

Further strengthens Poolbeg's global intellectual property portfolio

 

20 November 2025 - Poolbeg Pharma (https://www.poolbegpharma.com/)  (AIM:
POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company
with a core focus on transforming the cancer immunotherapy field, announces
that the European Patent Office has granted Poolbeg's European Immunomodulator
II patent application covering POLB 001 for the treatment of severe influenza.

 

POLB 001 is a potent and selective p38 MAP kinase inhibitor with strong
potential across multiple disease areas, including the prevention and
treatment of cancer immunotherapy-induced Cytokine Release Syndrome ("CRS"), a
potential market opportunity of over US$10 billion, and the treatment of
severe influenza. POLB 001 holds the potential to address significant unmet
needs affecting patients and healthcare systems globally.

 

Poolbeg is actively building a comprehensive, worldwide IP portfolio, with
patents covering use of p38 MAPK inhibitors in patients with severe influenza
and for the prevention and treatment of cancer immunotherapy-induced CRS. This
patent grant further strengthens the Company's robust intellectual property
portfolio, enhancing POLB 001's value and appeal to potential partners.

 

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said:
"This patent grant from the European Patent Office highlights the strong
progress we continue to make in developing and strengthening our IP portfolio
for POLB 001 across multiple disease indications. This further enhances the
value and attractiveness of POLB 001 for potential partners."

 

Enquiries

 

 Poolbeg Pharma Plc                                            +44 (0) 207 183 1499

 Jeremy Skillington, CEO                                       ir@poolbegpharma.com (mailto:ir@poolbegpharma.com)

 Ian O'Connell, CFO

  
 Cavendish Capital Markets Ltd (NOMAD & Joint Broker)          +44 (0) 207 220 0500

 Geoff Nash, Trisyia Jamaludin (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Harriet Ward (ECM)

  
 Shore Capital Stockbrokers Ltd (Joint Broker)                 +44 (0) 207 408 4090

 David Coaten, Harry Davies-Ball (Corporate Advisory)

Malachy McEntyre (Corporate Broking)
 J&E Davy (Joint Broker)                                       +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

  
 Optimum Strategic Communications                              +44 (0) 208 078 4357

 Nick Bastin, Vici Rabbetts, Elena Bates                       poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

  

 

About Poolbeg Pharma plc

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage
biopharmaceutical company with a core focus on transforming the cancer
immunotherapy field. The Company's lead asset, POLB 001, has the potential to
expand administration of cancer immunotherapies from centralised specialist
cancer centres into community hospitals by making the treatments safer through
the prevention of the life-threatening side effect, Cytokine Release Syndrome
(CRS). As such, POLB 001 could increase the number of patients that can
receive these life-saving treatments, thereby increasing the market
opportunity. Poolbeg is also advancing the development of a patient-friendly
therapy for obesity with an oral encapsulated GLP-1, offering a differentiated
approach within one of the world's largest markets. With multiple near-term
clinical value inflection points, and an experienced team with a proven track
record, Poolbeg is focussed on partnering its high value programmes that are
targeting large markets and addressing critical unmet medical needs.

 

Stay updated: Website (http://www.poolbegpharma.com) | Sign up for RNS
alerts
(https://www.poolbegpharma.com/investors/regulatory-news-email-alerts/#email-alerts)
| Presentation
(https://www.poolbegpharma.com/investors/events-presentations/)  | X
(https://x.com/PoolbegPharma)  | LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)

 

Forward-Looking Statements

This announcement may contain forward-looking statements and the words
"expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast",
"project" and similar expressions (or their negative) identify certain of
these forward-looking statements. The forward-looking statements in this
announcement are based on numerous assumptions and Poolbeg's present and
future business strategies and the environment in which Poolbeg expects to
operate in the future. Forward-looking statements involve inherent known and
unknown risks, uncertainties and contingencies because they relate to events
and depend on circumstances that may or may not occur in the future and may
cause the actual results, performance or achievements to be materially
different from those expressed or implied by such forward-looking statements.
These statements are not guarantees of future performance or the ability to
identify and consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Poolbeg's ability to control or estimate
precisely, such as future market conditions, currency fluctuations, the
behaviour of other market participants, the outcome of clinical trials, the
actions of regulators and other factors such as Poolbeg's ability to obtain
financing, changes in the political, social and regulatory framework in which
Poolbeg operates or in economic, technological or consumer trends or
conditions. Past performance should not be taken as an indication or guarantee
of future results, and no representation or warranty, express or implied, is
made regarding future performance. No person is under any obligation to update
or keep current the information contained in this announcement or to provide
the recipient of it with access to any additional relevant information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBLBFTMTABBIA



            Copyright 2019 Regulatory News Service, all rights reserved